University of Illinois Chicago · PharmacologySchistosomiasis Drug Development Unit
Pavel A Petukhov · Chicago, Illinois
Research Focus
Dr. Pavel A. Petukhov's lab focuses on developing new drugs to treat schistosomiasis, a disease caused by parasitic worms affecting over 200 million people worldwide. The research centers around a unique enzyme, thioredoxin glutathione reductase (TGR), which is crucial for the worm's survival but not present in humans. By inhibiting this enzyme, the lab aims to create effective treatments while avoiding drug resistance, a significant issue with the current medication.
schistosomiasisdrug developmentTGR inhibitorsantioxidant defensemedicinal chemistry
Research Aims
5AIM 01Identify small molecule inhibitors of the thioredoxin glutathione reductase enzyme.
AIM 02Optimize TGR inhibitors for enhanced potency and selectivity.
AIM 03Investigate the biochemical properties of TGR and its human counterparts.
AIM 04Test the efficacy of TGR inhibitors in preclinical animal models.
AIM 05Develop therapeutic strategies to combat schistosomiasis.
Skills the Lab Values
biochemical assayshigh-throughput screeningX-ray crystallographycryo-electron microscopycomputer-aided drug design
Output against the department
Publications119bottom 34% of dept.306th of 462
this lab
most publishedleast published
Citations2.8kbottom 21% of dept.366th of 462
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.